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The global epidemic of head injuries is just beginning. At
present, over one million people die each year and a similar
number are disabled from brain injuries, often with profound
effects on the quality of life of the affected individuals and
their carers [1].
Road traffic crashes account for most of the deaths, and car
use is rapidly increasing in many countries. It is estimated
that, by 2020, road traffic crashes will have moved from its
present position of ninth to third in the world disease burden
ranking, as measured in disability adjusted life years, and will
be ranked second in developing countries (Tables 1–3).
The identification of effective treatments for head injury is of
global health importance. The CRASH trial is the largest
randomised, controlled trial in head injury ever conducted;
almost 2000 patients have already been recruited. It will,
however, only be possible to reach the recruitment target of
20,000 if doctors and nurses worldwide join the trial and
help to make it a success. The protocol of the trial has been
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Abstract
The global epidemic of head injuries is just beginning. Many are caused by road traffic crashes. It is
estimated that, by 2020, road traffic crashes will have moved from its present position of ninth to third
in the world disease burden ranking, as measured in disability adjusted life years. In developing
countries, it will have moved to second. The Corticosteroid Randomisation After Significant Head Injury
(CRASH) trial is a large-scale, randomised, controlled trial, among adults with head injury and impaired
consciousness, of the effects of a short-term infusion of corticosteroids on death and on neurological
disability. Following a successful pilot phase, which included over 1000 randomised participants, the
main phase of the trial is now underway. Over the next 5 years, the trial aims to recruit a total of 20,000
patients. Such large numbers will only be possible if hundreds of doctors and nurses can collaborate in
emergency departments all over the world. The trial is currently recruiting, and new collaborators are
welcome to join the trial (see www.crash.lshtm.ac.uk).
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Table 1
World disease burden ranking in 1990
Causes DALYs (1000s) % total
Lower respiratory infections 112,898 8.19
Diarrhoeal diseases 99,633 7.22
Perinatal conditions 92,313 6.69
Unipolar major depression 50,810 3.68
Ischaemic heart disease 46,699 3.39
Cerebrovascular disease 38,523 2.79
Tuberculosis 38,426 2.79
Measles 36,520 2.65
Road traffic accidents 34,317 2.49
Congenital abnormalities 32,921 2.39
Road traffic accidents were the ninth largest burden worldwide in
1990 as measured by disability adjusted life years (DALY).
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published and is freely accessible online [2,3], and there is
also a website with further information and guidance [4].
The CRASH trial is a large-scale, randomised, controlled trial,
among adults with head injury and impaired consciousness,
of the effects of a short-term infusion of corticosteroids on
death and on neurological disability. Following a successful
pilot phase that included over 1000 randomised participants,
the main phase of the trial is now underway. The trial aims to
recruit a total of 20,000 patients over the next 5 years.
Why we need this trial
There are several reasons for conducting the CRASH trial at
the present time. First, animal studies have shown that high
dose methylprednisolone can reduce post-traumatic neuronal
degeneration [5,6]. Second, patients with spinal cord injury
who are treated with corticosteroids rather than placebo
within 8 hours of injury appear to have greater improvement
in motor function, and in sensation to pinprick and touch
[7,8]. Third, there are wide variations within and between
countries in the use of corticosteroids in head injury [9].
Finally, a meta-analysis of randomised trials of corticosteroids
in head injury shows that existing trials are too small to
demonstrate or to refute the possibility of a moderate but
clinically important benefit [10].
Keep it simple, recruit thousands
Head-injured adults with impaired consciousness are eligible
for inclusion in the trial if the responsible doctor is, for any
reason, uncertain of whether to use corticosteroids. Patients
with head injury and impaired consciousness may be unable
to give properly informed consent, and in this emergency
situation it may not be appropriate to delay the start of
treatment until relatives’ consent can be obtained. Hence, the
doctor in charge should take responsibility for entering such
patients, just as they would take responsibility for choosing
other treatments. However, the requirements of the research
ethics committee must be adhered to.
Numbered drug or placebo packs will be available in each
participating emergency department. Randomisation involves
calling a 24-hour free phone service. The call should last only
1 or 2 min, and at the end of it the service will specify which
numbered treatment pack to use. If, for any reason, telephone
randomisation is not feasible, randomisation can also be
carried out by fax.
The outcome measures are death from any cause within
2 weeks of injury, and death or dependence at 6 months.
In-hospital deaths, complications, and short-term recovery are
recorded on a single-sided outcome form that can be
completed entirely from the hospital notes. No extra tests are
needed. Long-term recovery is assessed at 6 months, either
by a simple postal questionnaire sent directly to each trial
participant from the national co-ordinating centre or by
telephone interview. It will not involve additional work for
collaborating hospitals.
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